Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 7/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.49 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.49 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457991 | 0.98 | CXCL8 (0.51) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL8053100 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL9618518 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL9618521 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| Potassium SCHEMBL8053105 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| Rubidium SCHEMBL9618522 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL29598223 | 0.97 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| Diethylamine SCHEMBL9790067 | 0.90 | CXCL8 (0.47) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL10412874 | 0.89 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL10413114 | 0.89 | CXCL8 (0.50) | CXCL8PTGS2TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55045615-A | — | — | None | — | — | JP | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9371284-B2 | Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| WO-2013005226-A1 | A NOVEL COMBINED PHARMACEUTICAL COMPOSITION CONTAINING DICLOFENAC AND METHODS OF MAKING AND USING THE SAME | ZOTA HEALTH CARE LTD (IN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2011081672-A1 | LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM | KULESZA JOHN E (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110142769-A1 | LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM | KULESZA JOHN E | 2011-06-16 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-1154999-B1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| US-6107343-A | GLAUCOMA THERAPY; CONCURRENT WITH GLUCOCORTIODS | NOVARTIS AG (CH) | 2000-08-22 | — | — | US | disclosed |
| US-5891913-A | ANTIINFLAMMATORY AGENT | NOVARTIS FINANCE CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| US-5681583-A | SUSTAINED RELEASE; THE DISINTEGRATING RATE OF FIRST LAYER IS FASTER THAN THE SECOND LAYER | APR APPLIED PHARMA RESEARCH SA (CH) | 1997-10-28 | — | — | US | disclosed |
| EP-0785780-A1 | OPHTHALMIC AND AURAL COMPOSITIONS CONTAINING DICLOFENAC POTASSIUM | Novartis AG (CH) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011003-A1 | OPHTHALMIC AND AURAL COMPOSITIONS CONTAINING DICLOFENAC POTASSIUM | NOVARTIS AG (CH) | 1996-04-18 | — | — | WO | disclosed |
| US-4829088-A | 2-AMINO-2-HYDROXYMETHYL-1,3-PROPANEDIOL AS STABILIZER | DISPERSA AG (CH) | 1989-05-09 | — | — | US | disclosed |
| EP-0017169-B1 | IMPROVED ANTI-INFLAMMATORY COMBINATIONS HAVING REDUCED ULCEROGENICITY | MERCK & CO. INC. (US) | 1983-03-09 | — | — | EP | disclosed |
| US-4362738-A | ANTIINFLAMMATORIES | DR. KARL THOMAE GMBH (DE) | 1982-12-07 | — | — | US | disclosed |
| JP-S5545615-A | DERIVATIVE OF (N-ALLYL-O-(2,6-DICHLOROANILINO) PHENYL) ACETIC ACID | NISSAN CHEM IND LTD | 1980-03-31 | — | — | JP | disclosed |
| US-4189595-A | [N-benzyl-o-(2,6-dichloroanilino)phenyl]acetic acid derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CXCL8 1267/4885PTGS2 270/4885TTR 1893/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | CXCL8 187/4885PTGS2 7/4885TTR 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.